JP2013511560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511560A5 JP2013511560A5 JP2012540229A JP2012540229A JP2013511560A5 JP 2013511560 A5 JP2013511560 A5 JP 2013511560A5 JP 2012540229 A JP2012540229 A JP 2012540229A JP 2012540229 A JP2012540229 A JP 2012540229A JP 2013511560 A5 JP2013511560 A5 JP 2013511560A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mirna
- mir
- cells
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001301 EGF receptor Human genes 0.000 claims 11
- 108060006698 EGF receptor Proteins 0.000 claims 11
- 108091070501 miRNA Proteins 0.000 claims 11
- 239000002679 microRNA Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108091023818 miR-7 stem-loop Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 8
- 239000002243 precursor Substances 0.000 claims 7
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 108091067625 Homo sapiens miR-7-1 stem-loop Proteins 0.000 claims 2
- 108091067630 Homo sapiens miR-7-2 stem-loop Proteins 0.000 claims 2
- 108091067633 Homo sapiens miR-7-3 stem-loop Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 230000036456 mitotic arrest Effects 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009905758 | 2009-11-24 | ||
| AU2009905758A AU2009905758A0 (en) | 2009-11-24 | Method of Modulating Epidermal Growth Factor (EGF) Ligands | |
| PCT/AU2010/001578 WO2011063456A1 (en) | 2009-11-24 | 2010-11-24 | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511560A JP2013511560A (ja) | 2013-04-04 |
| JP2013511560A5 true JP2013511560A5 (enExample) | 2014-01-16 |
Family
ID=44065735
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540228A Pending JP2013511559A (ja) | 2009-11-24 | 2010-11-24 | 上皮成長因子受容体リガンドのモジュレーション |
| JP2012540229A Pending JP2013511560A (ja) | 2009-11-24 | 2010-11-24 | チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540228A Pending JP2013511559A (ja) | 2009-11-24 | 2010-11-24 | 上皮成長因子受容体リガンドのモジュレーション |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9051551B2 (enExample) |
| EP (2) | EP2504014A4 (enExample) |
| JP (2) | JP2013511559A (enExample) |
| CN (2) | CN102762213A (enExample) |
| AU (2) | AU2010324529A1 (enExample) |
| CA (2) | CA2781572A1 (enExample) |
| DK (1) | DK2521555T3 (enExample) |
| ES (1) | ES2608923T3 (enExample) |
| WO (2) | WO2011063456A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| EP2591106A1 (en) * | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| BR112014012495A2 (pt) * | 2011-11-25 | 2017-06-06 | Assist Publique - Hopitaux De Paris | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |
| FR2984168B1 (fr) * | 2011-12-19 | 2019-07-05 | Chanel Parfums Beaute | Micro-rna pour leur utilisation dans la pigmentation |
| US20150126621A1 (en) * | 2012-05-15 | 2015-05-07 | New York University | METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS |
| IN2015DN04209A (enExample) * | 2012-10-18 | 2015-10-16 | Univ Western Australia | |
| WO2014143855A2 (en) * | 2013-03-15 | 2014-09-18 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| US20140308274A1 (en) * | 2013-03-15 | 2014-10-16 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors |
| CA2919477A1 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| CN108537001B (zh) * | 2018-04-12 | 2021-06-01 | 华中科技大学鄂州工业技术研究院 | 一种预测用于治疗肝癌的特异性治疗药物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1797183T3 (da) * | 2004-09-02 | 2012-10-01 | Univ Yale | Regulering af onkogener med mikrornas |
| ES2534300T3 (es) * | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| ES2534430T3 (es) | 2006-08-28 | 2015-04-22 | The University Of Western Australia | Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN |
| EP2104737B1 (en) | 2006-12-08 | 2013-04-10 | Asuragen, INC. | Functions and targets of let-7 micro rnas |
| US20100173954A1 (en) | 2007-01-19 | 2010-07-08 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
-
2010
- 2010-11-24 US US13/511,181 patent/US9051551B2/en active Active
- 2010-11-24 AU AU2010324529A patent/AU2010324529A1/en not_active Abandoned
- 2010-11-24 CN CN2010800604001A patent/CN102762213A/zh active Pending
- 2010-11-24 AU AU2010324530A patent/AU2010324530B2/en not_active Ceased
- 2010-11-24 JP JP2012540228A patent/JP2013511559A/ja active Pending
- 2010-11-24 ES ES10832418.7T patent/ES2608923T3/es active Active
- 2010-11-24 CA CA2781572A patent/CA2781572A1/en not_active Abandoned
- 2010-11-24 DK DK10832418.7T patent/DK2521555T3/en active
- 2010-11-24 EP EP10832417.9A patent/EP2504014A4/en not_active Withdrawn
- 2010-11-24 CA CA2781571A patent/CA2781571A1/en not_active Abandoned
- 2010-11-24 JP JP2012540229A patent/JP2013511560A/ja active Pending
- 2010-11-24 CN CN2010800604035A patent/CN102762214A/zh active Pending
- 2010-11-24 EP EP10832418.7A patent/EP2521555B1/en active Active
- 2010-11-24 WO PCT/AU2010/001578 patent/WO2011063456A1/en not_active Ceased
- 2010-11-24 US US13/511,183 patent/US20130090366A1/en not_active Abandoned
- 2010-11-24 WO PCT/AU2010/001577 patent/WO2011063455A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Transforming growth factor β signaling pathway: A promising therapeutic target for cancer | |
| Zhang et al. | The roles of ZEB1 in tumorigenic progression and epigenetic modifications | |
| Oh et al. | Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras | |
| Ueno et al. | Targeting EGFR in triple negative breast cancer | |
| Finlay et al. | Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden | |
| CN101951926B (zh) | 包含微小rna-21抑制剂的增强辐射敏感性的组合物 | |
| JP2014526456A5 (enExample) | ||
| Li et al. | MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A | |
| Zhao et al. | miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor | |
| Tan et al. | Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT | |
| Gu et al. | Suppressing the secretion of exosomal miR-19b by gw4869 could regulate oxaliplatin sensitivity in colorectal cancer. | |
| Cai et al. | Effects of miR-150 on neuropathic pain process via targeting AKT3 | |
| Fan et al. | MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1. | |
| JP2013511559A5 (enExample) | ||
| Ren et al. | An update on RNA interference-mediated gene silencing in cancer therapy | |
| Carrasco-Garcia et al. | Therapeutic strategies targeting glioblastoma stem cells | |
| Bhatia et al. | miRNAs are now starring in “No Time to Die: Overcoming the chemoresistance in cancer” | |
| JP2011520781A5 (enExample) | ||
| Parra et al. | The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines | |
| Tao et al. | Role of microRNA in prostate cancer stem/progenitor cells regulation. | |
| WO2012058462A3 (en) | Combination therapy for the treatment of cancer | |
| Wang et al. | Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma | |
| Zhang et al. | Synthesis and Biological Activity of Multi-targeting Platinum (Ⅱ) Anticancer Complexes | |
| Farooqi et al. | Regulation of Kisspeptin mediated signaling by non-coding RNAs in different cancers: the beginning of a new era | |
| Inoue et al. | Surmounting chemoresistance by targeting the Y‐box binding protein‐1 |